Literature DB >> 26810725

Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.

Berit Jordan1, Juliane Kellner2, Karin Jordan3, Manfred Bähre4, Curd Behrmann5, Stephan Zierz2.   

Abstract

Precise diagnostic work up of a suspected thymic pathology in patients with myasthenia gravis (MG) is very important for potential surgical implications and further disease course. In this study the diagnostic value of combined preoperative radiological (CAT scan) and nuclear based imaging (octreotide and thallium scintigraphy) in patients with MG was evaluated. Twenty four patients were included. Histopathology revealed thymoma in nine patients, thymic carcinoma (TC) in one patient, lymphofollicular hyperplasia in seven patients, and involuted thymus in another seven patients. Diagnostic sensitivity for detecting thymoma/TC was 80 % in CAT scan as well as in somatostatin scintigraphy; the combination of both procedures reached 90 %. However, the diagnostic specifity to exclude thymoma in CAT scan was 100 % and in octreotide scintigraphy 85.7 %. Semiquantitative octreotide uptake significantly correlated with histological grading of thymoma/TC (r = 0.764) and histological proliferation rate Ki67 (r = 0.894). Thallium scintigraphy was positive only in one out of four thymoma cases. In this study, somatostatin scintigraphy has been shown to be a useful additional diagnostic technique in detecting thymic malignancies in patients with MG. These results might be especially helpful in patients with late onset MG as these patients are in general no candidates for thymectomy.

Entities:  

Keywords:  Myasthenia gravis; Octreotide scintigraphy; Thallium scintigraphy; Thymic pathology; Thymoma

Mesh:

Year:  2016        PMID: 26810725     DOI: 10.1007/s00415-016-8023-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.

Authors:  A Nikolic; P Djukic; I Basta; Lj Hajdukovic; V Rakocevic Stojanovic; Z Stevic; D Nikolic; V Bozic; S Lavrnic; D Lavrnic
Journal:  Clin Neurol Neurosurg       Date:  2012-07-06       Impact factor: 1.876

Review 2.  Somatostatin receptors in the thymus.

Authors:  D Ferone; P M van Hagen; A Colao; L Annunziato; S W Lamberts; L J Hofland
Journal:  Ann Med       Date:  1999-10       Impact factor: 4.709

Review 3.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.

Authors:  Sonia Berrih-Aknin; Rozen Le Panse
Journal:  J Autoimmun       Date:  2014-01-03       Impact factor: 7.094

4.  Thymic lesions in patients with myasthenia gravis: characterization with thallium 201 scintigraphy.

Authors:  T Higuchi; J Taki; S Kinuya; M Yamada; M Kawasuji; O Matsui; A Nonomura; H Bunko; N Tonami
Journal:  Radiology       Date:  2001-10       Impact factor: 11.105

Review 5.  Thymoma related myasthenia gravis in humans and potential animal models.

Authors:  Alexander Marx; Stefan Porubsky; Djeda Belharazem; Güher Saruhan-Direskeneli; Berthold Schalke; Philipp Ströbel; Cleo-Aron Weis
Journal:  Exp Neurol       Date:  2015-02-18       Impact factor: 5.330

6.  Surgical resection of thymoma still represents the first choice of treatment.

Authors:  M Ried; H Guth; T Potzger; C Diez; R Neu; B Schalke; H-S Hofmann
Journal:  Thorac Cardiovasc Surg       Date:  2011-06-20       Impact factor: 1.827

Review 7.  Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor.

Authors:  A M Priola; S M Priola
Journal:  Clin Radiol       Date:  2014-02-26       Impact factor: 2.350

8.  In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue.

Authors:  J C Reubi; B Waser; U Horisberger; E Krenning; S W Lamberts; J O Gebbers; P Gersbach; J A Laissue
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

9.  ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.

Authors:  Alexander Marx; Philipp Ströbel; Sunil S Badve; Lara Chalabreysse; John K C Chan; Gang Chen; Laurence de Leval; Frank Detterbeck; Nicolas Girard; Jim Huang; Michael O Kurrer; Libero Lauriola; Mirella Marino; Yoshihiro Matsuno; Thierry Jo Molina; Kiyoshi Mukai; Andrew G Nicholson; Daisuke Nonaka; Ralf Rieker; Juan Rosai; Enrico Ruffini; William D Travis
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

10.  Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis.

Authors:  Berit Jordan; Susanne Schilling; Stephan Zierz
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.